Skip to content

Stock-Based Comp at other companies

Incyte logo
IncyteINCY
$64.13M+5.2%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$43.46M+15.3%
UroGen Pharma logo
UroGen PharmaURGN
$4.63M+50.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$33.24M+28.4%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$5.49M+142%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$12.05M+16.1%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s stock-based comp?
Tyra Biosciences, Inc. (TYRA) reported stock-based comp of $7.85M in Q1 2026.
How has Tyra Biosciences, Inc.'s stock-based comp changed year-over-year?
Tyra Biosciences, Inc.'s stock-based comp increased by 22.2% year-over-year, from $6.42M to $7.85M.
What is the long-term trend for Tyra Biosciences, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s stock-based comp has grown at a 76.5% compound annual growth rate (CAGR), from $2.89M to $28.01M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.